Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients

Summary

Our hypothesis is that treating ARDS caused by COVID-19 with bevacizumab improves mortality. This is a phase II, multi-centered, randomized, open label, two-armed clinical trial to study the safety and efficacy of bevacizumab in COVID-19 positive patients who consequently developed ARDS (acute respiratory distress syndrome) and who have previously received anti-viral and anti-inflammatory treatment.

Timeline

Start

2020-09-01

Primary completion

2021-08-31

Completion

2021-08-31

Outcome

Outcome not reported

Stopped (Business): “Lack of financing, lack of COVID19 patients in the ICU.”

Drugs

Indications